BioCentury
ARTICLE | Clinical News

Apellis reports 18-month Phase II data for GA candidate

February 23, 2018 8:35 PM UTC

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment. GA is an advanced form of dry age-related macular degeneration (AMD).

FILLY enrolled 246 patients with GA to receive sham injections or intravitreal injections of APL-2 monthly or every other month for 12 months, followed by a six-month monitoring period with no active treatment. Once-monthly APL-2 for 12 months reduced GA lesion growth from baseline to 18 months by 20.4% vs. sham control (p=0.044) and APL-2 given every other month for 12 months reduced GA lesion growth from baseline to 18 months by 16.3% vs. sham control (p=0.097). The pre-specified threshold for significance in the trial was a p-value of <0.1...